Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Inflammation and the immune system

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Many approaches have been undertaken to understand Alzheimer's disease (AD) but the heterogeneity of the etiologic factors makes it difficult to define the clinically most important factor determining the onset and progression of the disease. However, there is increasing evidence that the previously so-called "secondary factors" such as a disturbed glucose metabolism, oxidative stress and formation of "advanced glycation endproducts" (AGEs) and their interaction in a vicious cycle are also important for the onset and progression of AD. AGEs are protein modifications that contribute to the formation of the histopathological and biochemical hallmarks of AD: amyloid plaques, neurofibrillary tangles and activated microglia.

What this study adds

Evidence grade: Low

This is a narrative review. This paper proposes that disturbed glucose metabolism, oxidative stress and advanced glycation endproducts interact in a vicious cycle that contributes to the onset and progression of Alzheimer's disease. It is a review of evidence rather than a clinical trial, so it does not show that targeting these factors treats or prevents the disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Münch, G., Schinzel, R., Loske, C., Wong, A., Durany, N., Li, J. J., et al. (1998). Alzheimer's disease--synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. Journal of neural transmission (Vienna, Austria : 1996). https://doi.org/10.1007/s007020050069

Vancouver

Münch G, Schinzel R, Loske C, Wong A, Durany N, Li JJ, et al. Alzheimer's disease--synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. Journal of neural transmission (Vienna, Austria : 1996). 1998. doi:10.1007/s007020050069. PMID: 9720973.

BibTeX

@article{munch1998-9720973,
  author  = {Münch, G. and Schinzel, R. and Loske, C. and Wong, A. and Durany, N. and Li, J. J. and Vlassara, H. and Smith, M. A. and others},
  title   = {{Alzheimer's disease--synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts}},
  journal = {Journal of neural transmission (Vienna, Austria : 1996)},
  year    = {1998},
  doi     = {10.1007/s007020050069},
  pmid    = {9720973},
  url     = {https://doi.org/10.1007/s007020050069}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This paper proposes that disturbed glucose metabolism, oxidative stress and advanced glycation endproducts interact in a vicious cycle that contributes to the onset and progression of Alzheimer's disease. It is a review of evidence rather than a clinical trial, so it does not show that targeting these factors treats or prevents the disease.

Study details

How this study scored 47/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 6 of 7; Citations per year 3 of 5; Impact for its field and year 4 of 6; Cited by studies here 3 of 6; Still being cited 2 of 4; Senior author's track record 4 of 4; Institution's track record 1 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 47 of 100.47 of 100 points earned53 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of neural transmission (Vienna, Austria : 1996))
Journal's citation record 2 / 4 Journal of Neural Transmission: journal h-index 167 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 1998 — older than 20 years, still counted
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 6 / 7 Cited 304 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 10.1 citations a year over 30 year(s) since 1998
Impact for its field and year 4 / 6 Cited 9.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 13 other studies in this library
Still being cited 2 / 4 Cited 20 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Peter Franz Riederer: h-index 108 (OpenAlex, whole career)
Institution's track record 1 / 3 Case Western Reserve University: institution h-index 1,159 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 9720973)
Free to read 0 / 2 Behind a paywall — scores zero
Total 47 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

13 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Inflammation and the immune system from nearby years

Also in Inflammation and the immune system

138 studies in the library are filed under Inflammation and the immune system with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Inflammation and the immune system hub.

Similar studies

More on Inflammation and the immune system

See all studies in Inflammation and the immune system →